Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
We need your help to provide it. Donate today to keep election news free for everyone.